

15 September 2025

Business Update – Initial German Purchase Orders and Import Permits

Bioxyne Limited (ASX: BXN) (Bioxyne or Company), through its local partner in Germany, has received import authorisations from the German Government for 1,550kg of medical cannabis products.

On 18 June the Company announced it entered the German cannabis market, executing a commercial agreement to supply a minimum of A\$5.6m of GMP medical cannabis flower product manufactured by BLS in Australia in FY2026.

As of 10 September, the Company has received purchase orders from its German clients for A\$5.1m with export to Germany planned for end of September/ early October.

Farmakem and Adrex have forecasted reorders in November, January, March, and May, (subject to import / export permitting and local market conditions), with forecast outlook expected to exceed the \$5.6m contracted under the June 2025 Supply Agreement¹.

About Bioxyne Limited:

Bioxyne Limited is a licensed Australian pharmaceutical and healthcare company manufacturing and distributing novel medicines, health products and active pharmaceutical ingredients including medicinal cannabis, MDMA, and Psilocybin.

<https://bioxyne.com>

This announcement has been approved by the Board for release to the ASX.

For further information, please contact:

Bioxyne Limited
Investor Relations
Email: info@bioxyne.com
Phone: +61 2 9078 8180

¹ ASX Announcement 18 June 2025 "Bioxyne enters German market with €3,200,000 (A\$5.6m) minimum Manufacture and Supply Agreement".

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription medicines in Australia.
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.
- c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
 - **United Kingdom:** drwatsoncbd.com
 - **Japan:** nolcbn.com
 - **UK / EU:** breathelifesciences.com
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com

